





an Open Access Journal by MDPI

# Advanced Research in Endocrine Tumor: Molecular Pathology, Biomarker and Target Therapy

Guest Editor:

#### Prof. Dr. Yasuhiro Nakamura

Division of Pathology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Miyagi 981-8558, Japan

Deadline for manuscript submissions:

closed (30 April 2022)

# Message from the Guest Editor

Dear Colleagues,

Recent developments in molecular analyzing systems have clarified pathogenesis, novel biomarkers, and prognostic prediction of several types of endocrine tumors, which has resulted in significant revisions in the fourth edition of the World Health Organization's classification of endocrine tumors. Therefore, it would be very interesting to specifically focus on these novel findings. I invite you to submit an original and review article for this Special Edition. It would be an honor to work and co-publish with you.

Prof. Dr. Yasuhiro Nakamura Guest Editor







IMPACT FACTOR 4.7

Indexed in: PubMed CITESCORE 3.7

an Open Access Journal by MDPI

## **Editor-in-Chief**

## Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

# **Message from the Editor-in-Chief**

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous*))

#### **Contact Us**